11-dehydro Thromboxane B2 EIA Kit - Monoclonal

Thromboxane A2 (TXA2), produced from arachidonic acid, causes irreversible platelet aggregation, vascular, and bronchial smooth muscle contraction. TXA2 is rapidly hydrolyzed non-enzymatically to form TXB2. However, most of the TXB2 measured in the plasma or urine of healthy individuals is due to ex vivo platelet activation or intra-renal production, and normal concentrations of circulating TXB2 are extremely low (1-2 pg/ml) and highly transient (t1/2 = 5-7 minutes). 11-dehydro TXB2 is a metabolite of TXB2 (not formed by platelets or the kidney) with a circulating half-life (t1/2) of 45 minutes. Its measurement in plasma or urine will give a time-integrated indication of TXA2 production and is recommended to estimate TXA2 levels to circumvent measurement complications associated with TXB2. Cayman's 11-dehydro TXB2 EIA Kit is a competitive assay that can be used for quantification of 11-dehydro TXB2 in urine and other sample matrices. Normal plasma levels of 11-dehydro TXB2 (1-2 pg/ml) are below the detection limit of this assay (16 pg/ml), so plasma samples must be purified and concentrated prior to analysis. Urine samples should be diluted appropriately before assaying. There is evidence suggesting that 11-dehydro TXB2 can be formed non-enzymatically following platelet activation, so it is important to process plasma samples quickly to prevent artifactual formation of 11-dehydro TXB2. The EIA typically displays an IC50 (50% B/B0) value of 120 pg/ml and a detection limit (80% B/B0) of approximately 34 pg/ml.

Prices direct from Cayman Chemical Company

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

519510

Form

96 Well

P Type

Assay Kits|Eicosanoids|Thromboxanes

Weight

0

Storage Temp

-20

Shipping Temp

-20

Additional Info

Thromboxane A2 (TXA2), produced from arachidonic acid, causes irreversible platelet aggregation, vascular, and bronchial smooth muscle contraction. TXA2 is rapidly hydrolyzed non-enzymatically to form TXB2. However, most of the TXB2 measured in the plasma or urine of healthy individuals is due to ex vivo platelet activation or intra-renal production, and normal concentrations of circulating TXB2 are extremely low (1-2 pg/ml) and highly transient (t1/2 = 5-7 minutes). 11-dehydro TXB2 is a metabolite of TXB2 (not formed by platelets or the kidney) with a circulating half-life (t1/2) of 45 minutes. Its measurement in plasma or urine will give a time-integrated indication of TXA2 production and is recommended to estimate TXA2 levels to circumvent measurement complications associated with TXB2. Cayman's 11-dehydro TXB2 EIA Kit is a competitive assay that can be used for quantification of 11-dehydro TXB2 in urine and other sample matrices. Normal plasma levels of 11-dehydro TXB2 (1-2 pg/ml) are below the detection limit of this assay (16 pg/ml), so plasma samples must be purified and concentrated prior to analysis. Urine samples should be diluted appropriately before assaying. There is evidence suggesting that 11-dehydro TXB2 can be formed non-enzymatically following platelet activation, so it is important to process plasma samples quickly to prevent artifactual formation of 11-dehydro TXB2. The EIA typically displays an IC50 (50% B/B0) value of 120 pg/ml and a detection limit (80% B/B0) of approximately 34 pg/ml.